{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:09:59Z","timestamp":1792285799292,"version":"4.4.0"},"reference-count":24,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,6]]},"abstract":"<jats:p>A novel therapy, intralesional (IL) pentamidine, was compared to intralesional therapy with antimony (ILSb), a World Health Organization\u2013recommended therapy, for single Bolivian <jats:italic>Leishmania braziliensis<\/jats:italic> lesions. In Study 1, 90 patients were randomized equally between three injections of ILSb over 5 days, five injections of ILSb over 11 days, and three injections of IL pentamidine (120 \u03bcg\/mm<jats:sup>2<\/jats:sup> lesion area [ILPenta-120-3]) over 5 days. Cure rates at 6 months were 57% for ILSb-3 injections, 73% for ILSb-5 injections, and 72% for ILPenta-120-3 injections. Adverse effects were local irritation and injection-site pain\u2014ILSb (60 patients): mild (25), moderate (4); IL pentamidine (30 patients): mild (4), moderate (3). In Study 2, 60 patients were randomized equally between five injections of ILSb and three injections of a double dose of IL pentamidine (240 \u03bcg\/mm<jats:sup>2<\/jats:sup> [ILPenta-240-3]). In Study 2, cure rates were 67% for ILSb-5 injections and 73% for ILPenta-240-3. For three IL injections of pentamidine, efficacy was optimized at a dose of 120 \u03bcg\/mm<jats:sup>2<\/jats:sup> lesion area. The cure rate of that regimen was similar to that for ILSb-5 injections and nonstatistically larger than that of ILSb-3 injections. IL pentamidine is an attractive alternative to ILSb on the basis of efficacy for Bolivian <jats:italic>L. braziliensis<\/jats:italic>, the threat of Sb-resistant parasites, tolerance, and patient convenience of three visits over 5 days.<\/jats:p>","DOI":"10.4269\/ajtmh.15-0640","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T03:43:42Z","timestamp":1456199022000},"page":"852-856","source":"Crossref","is-referenced-by-count":37,"title":["Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis"],"prefix":"10.4269","volume":"94","author":[{"given":"Jaime","family":"Soto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Quispe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"ref1","series-title":"Clin Infect Dis","first-page":"1255","article-title":"Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis","volume":"56","author":"Soto","year":"2013"},{"key":"ref2","series-title":"J Infect Dis","first-page":"83","article-title":"An in vitro model for investigation of chemotherapeutic agents in leishmaniasis","volume":"142","author":"Berman","year":"1980"},{"key":"ref3","series-title":"Anfoleish (CL)","author":"DNDi","year":"2015"},{"key":"ref4","article-title":"PubMed search for \u201cPentamidine and Intralesional\u201d on August 5, 2015"},{"key":"ref5","series-title":"Control of the Leishmaniases","author":"World Health Organization","year":"2010"},{"key":"ref6","series-title":"Int Health","first-page":"153","article-title":"Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis","volume":"4","author":"Blum","year":"2012"},{"key":"ref7","series-title":"Clin Infect Dis","first-page":"1502","article-title":"Concerns about topical treatment for New World cutaneous leishmaniasis","volume":"57","author":"Monge-Maillo","year":"2013"},{"key":"ref8","series-title":"Clin Infect Dis","first-page":"1503","article-title":"Reply to Monge-Maillo et al","volume":"57","author":"Soto","year":"2013"},{"key":"ref9","series-title":"J Travel Med","first-page":"116","article-title":"LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014","volume":"21","author":"Blum","year":"2014"},{"key":"ref10","series-title":"Int J Dermatol","first-page":"56","article-title":"Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection","volume":"29","author":"el Darouti","year":"1990"},{"key":"ref11","series-title":"Ann Trop Med Parasitol","first-page":"493","article-title":"The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis","volume":"97","author":"Asilian","year":"2003"},{"key":"ref12","series-title":"Int J Dermatol","first-page":"281","article-title":"Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis","volume":"43","author":"Asilian","year":"2004"},{"key":"ref13","series-title":"Int J Dermatol","first-page":"1115","article-title":"Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis","volume":"45","author":"Salmanpour","year":"2006"},{"key":"ref14","series-title":"Int J Dermatol","first-page":"463","article-title":"Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil: an area of Leishmania (V.) braziliensis transmission","volume":"36","author":"Oliveira-Neto","year":"1997"},{"key":"ref15","series-title":"Am J Trop Med Hyg","first-page":"257","article-title":"Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006)","volume":"87","author":"Vasconcellos","year":"2012"},{"key":"ref16","series-title":"Am J Trop Med Hyg","first-page":"107","article-title":"Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine","volume":"50","author":"Soto","year":"1994"},{"key":"ref17","series-title":"Exp Parasitol","first-page":"78","article-title":"Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure","volume":"69","author":"Gr\u00f6gl","year":"1989"},{"key":"ref18","series-title":"PLoS Negl Trop Dis","first-page":"e491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","volume":"3","author":"Miranda-Verastegui","year":"2009"},{"key":"ref19","series-title":"Am J Trop Med Hyg","first-page":"351","article-title":"Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis","volume":"83","author":"V\u00e9lez","year":"2010"},{"key":"ref20","series-title":"PLoS Negl Trop Dis","first-page":"e912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010"},{"key":"ref21","series-title":"Am J Trop Med Hyg","first-page":"255","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011"},{"key":"ref22","series-title":"Am J Trop Med Hyg","first-page":"551","article-title":"Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis","volume":"84","author":"Newlove","year":"2011"},{"key":"ref23","series-title":"Parasitol Res","first-page":"1319","article-title":"Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs","volume":"101","author":"Hadighi","year":"2007"},{"key":"ref24","series-title":"J Infect Dis","first-page":"1168","article-title":"American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility?","volume":"194","author":"Yardley","year":"2006"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/94\/4\/article-p852.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/94\/4\/article-p852.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/94\/4\/article-p852.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:08:51Z","timestamp":1723068531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/94\/4\/article-p852.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":24,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.15-0640","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,6]]}}}